DK2595485T3 - Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser - Google Patents

Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser Download PDF

Info

Publication number
DK2595485T3
DK2595485T3 DK11810350.6T DK11810350T DK2595485T3 DK 2595485 T3 DK2595485 T3 DK 2595485T3 DK 11810350 T DK11810350 T DK 11810350T DK 2595485 T3 DK2595485 T3 DK 2595485T3
Authority
DK
Denmark
Prior art keywords
procedures
treatment
mediated disorders
sigma receptor
amid derivatives
Prior art date
Application number
DK11810350.6T
Other languages
Danish (da)
English (en)
Inventor
Lorenzo Pellegrini
Argeris N Karabelas
Remy Henri Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Application granted granted Critical
Publication of DK2595485T3 publication Critical patent/DK2595485T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK11810350.6T 2010-07-20 2011-07-20 Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser DK2595485T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36608010P 2010-07-20 2010-07-20
PCT/US2011/044698 WO2012012543A1 (en) 2010-07-20 2011-07-20 Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders

Publications (1)

Publication Number Publication Date
DK2595485T3 true DK2595485T3 (da) 2022-05-30

Family

ID=45497167

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11810350.6T DK2595485T3 (da) 2010-07-20 2011-07-20 Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser

Country Status (15)

Country Link
US (4) US20130274290A1 (https=)
EP (2) EP2595485B1 (https=)
JP (3) JP2013531073A (https=)
KR (1) KR101867634B1 (https=)
CN (2) CN103108548A (https=)
BR (1) BR112013001302A2 (https=)
CA (2) CA2805904C (https=)
DK (1) DK2595485T3 (https=)
ES (1) ES2914120T3 (https=)
HU (1) HUE058736T2 (https=)
PL (1) PL2595485T3 (https=)
PT (1) PT2595485T (https=)
RU (2) RU2746871C2 (https=)
TW (1) TWI520949B (https=)
WO (1) WO2012012543A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
WO2015191554A1 (en) * 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
ES2910528T3 (es) * 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
SG11201810358YA (en) * 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
KR102886241B1 (ko) 2018-08-21 2025-11-14 미쓰비시 타나베 파마 코퍼레이션 음성 증상 및 장애를 치료하고, 신경가소성을 증가시키고, 신경보호를 촉진시키기 위한 롤루페리돈의 용도
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497843A4 (en) * 1989-10-27 1992-09-23 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
NZ235841A (en) * 1989-10-27 1993-03-26 Du Pont (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions
NZ251610A (en) * 1992-04-23 1996-02-27 Merrell Dow Pharma 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions
NZ521576A (en) * 2000-02-29 2005-06-24 Mitsubishi Pharma Corp Novel cyclic amide derivatives
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them

Also Published As

Publication number Publication date
US20250228838A1 (en) 2025-07-17
EP2595485A4 (en) 2014-04-23
PT2595485T (pt) 2022-05-30
US20210106573A1 (en) 2021-04-15
JP2013531073A (ja) 2013-08-01
RU2013107378A (ru) 2014-08-27
BR112013001302A2 (pt) 2017-07-04
HUE058736T2 (hu) 2022-09-28
JP6419294B2 (ja) 2018-11-07
RU2017105262A (ru) 2019-01-18
EP4070794A2 (en) 2022-10-12
CN107007603A (zh) 2017-08-04
EP2595485B1 (en) 2022-03-16
JP2018065829A (ja) 2018-04-26
KR101867634B1 (ko) 2018-06-15
EP2595485A1 (en) 2013-05-29
CA2805904A1 (en) 2012-01-26
PL2595485T3 (pl) 2022-06-20
ES2914120T3 (es) 2022-06-07
JP2016199578A (ja) 2016-12-01
CN103108548A (zh) 2013-05-15
KR20130129906A (ko) 2013-11-29
EP4070794A3 (en) 2023-01-18
US20160354357A1 (en) 2016-12-08
RU2746871C2 (ru) 2021-04-21
RU2613201C2 (ru) 2017-03-15
TW201211022A (en) 2012-03-16
CA2805904C (en) 2022-06-21
CA3154027A1 (en) 2012-01-26
WO2012012543A1 (en) 2012-01-26
TWI520949B (zh) 2016-02-11
US20130274290A1 (en) 2013-10-17
RU2017105262A3 (https=) 2019-01-18

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
PL2504005T3 (pl) Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
LT2558105T (lt) Bardoksolono metilas, skirtas nutukimo gydymui
DK2853265T3 (da) Fremgangsmåder til at øge stabiliseringen af hypoxi-inducerbar faktor-1-alpha
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DE112013002528A5 (de) Kopfhalterung zur Fixierung des Kopfes von Patienten
IL225668A (en) Formulations for the treatment of disorders of the upper respiratory tract
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
PL2427193T3 (pl) Zastosowanie inhibitorów pde7 do leczenia zaburzeń ruchu
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
PT2797581T (pt) Formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanossulfonil-etil]-4-acetilaminoisoindolino-1,3-diona
EP2776564A4 (en) MODULATION OF TMPRSS6.EXPRESSION
DK2903432T3 (da) Fremgangsmåde til behandling af sædceller til kønsortering
DK2595485T3 (da) Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af sigma-receptormedierede forstyrrelser
LT2812013T (lt) Kompozicija, skirta džs gydymui
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
DK2705847T3 (da) Sammensætning til behandling af psoriasis
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi